Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Other Non-Current Liabilities (2018 - 2025)

Plus Therapeutics (PSTV) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $25.1 million as the latest value for Q1 2025.

  • Quarterly Other Non-Current Liabilities changed N/A to $25.1 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $25.1 million through Mar 2025, changed N/A year-over-year, with the annual reading at $7000.0 for FY2020, 99.9% down from the prior year.
  • Other Non-Current Liabilities for Q1 2025 was $25.1 million at Plus Therapeutics, up from $3000.0 in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $25.1 million in Q1 2025, with the low at $3000.0 in Q3 2021.